Lv4
710 积分 2025-09-16 加入
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC
1天前
已完结
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer
1个月前
已完结
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
2个月前
已完结
Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis
2个月前
已完结
LGI3 promotes the progression of TFE3-rearranged renal cell carcinoma through GEMIN6/AURKB axis
3个月前
已完结
NRF2 has a splicing regulatory function involving the survival of motor neuron (SMN) in non-small cell lung cancer
4个月前
已完结
Geminin expression in small lung adenocarcinomas: implication of prognostic significance
5个月前
已完结
LGI3 promotes the progression of TFE3-rearranged renal cell carcinoma through GEMIN6/AURKB axis
5个月前
已完结
Identification of Defined Molecular Subgroups on the Basis of Immunohistochemical Analyses and Potential Therapeutic Vulnerabilities of Pulmonary Carcinoids
5个月前
已完结
Interactions of Fatty Acid and Cholesterol Metabolism with Cellular Stress Response Pathways in Cancer
5个月前
已完结
皖公网安备34019202002308
